# A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-randomised-two-arm-1-1-ratio-double-blind-placebo-controlled-phase-iii-trial/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Lisa Willcocks,Wendi Qian,Ruzaika Cader,Katrina Gatley,Hira Siddiqui,Endurance Tabebisong,Karlena Champion,Andreas Kronbichler,Liz Lightstone,David Jayne,Edward Wilson,Megan Griffith |
| Citations | 7 |
| DOI | 10.1186/s12882-024-03576-0 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://bmcnephrol.biomedcentral.com/counter/pdf/10.1186/s12882-024-03576-0 |
| OpenAlex ID | https://openalex.org/W4401384937 |
| PMID | 39112932 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Ruzaika Cader](https://scholariq.org/researchers/ruzaika-cader/)

## Paper journal

- [BMC Nephrology](https://scholariq.org/journals/bmc-nephrology/)

## Paper primary topic

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Paper topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.